2. Search Result
Search Result
Results for "

RGDS

" in MedChemExpress (MCE) Product Catalog:

78

Inhibitors & Agonists

1

Fluorescent Dye

5

Biochemical Assay Reagents

57

Peptides

1

Inhibitory Antibodies

5

Natural
Products

2

Isotope-Labeled Compounds

5

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P0278
    RGD
    5+ Cited Publications

    		 Integrin Cancer
    RGD is a tripeptide that effectively triggers cell adhesion, addresses certain cell lines and elicits specific cell responses; binds to integrins.
    RGD
  • HY-12290
    Arg-Gly-Asp-Ser
    Maximum Cited Publications
    9 Publications Verification

    RGDS peptide; Fibronectin tetrapeptide

    		 Integrin Inflammation/Immunology
    Arg-Gly-Asp-Ser is an integrin binding sequence that inhibits integrin receptor function. Arg-Gly-Asp-Ser directly and specifically bind pro-caspase-8, pro-caspase-9 and pro-caspase-3, while it does not bind pro-caspase-1.
    Arg-Gly-Asp-Ser
  • HY-P1740
    RGD peptide (GRGDNP)
    5+ Cited Publications

    		 Integrin Apoptosis Caspase Inflammation/Immunology
    RGD peptide (GRGDNP) is an inhibitor of integrin-ligand interactions. RGD peptide (GRGDNP) competitively inhibits α5β1 binding with extracellular matrice (ECM). RGD peptide (GRGDNP) promotes apoptosis through activation of conformation changes that enhance pro-caspase-3 activation and autoprocessing. RGD peptide (GRGDNP) plays an important role in cell adhesion, migration, growth, and differentiation .
    RGD peptide (GRGDNP)
  • HY-166648
    DSPE-PEG2000-Maleimide sodium (purity>99%)
    1 Publications Verification

    		 Liposome Cancer
    DSPE-PEG2000-Maleimide sodium (purity>99%) is a functional lipid component and a thiol-reactive crosslinker. DSPE-PEG2000-Maleimide sodium (purity>99%) undergoes Michael addition with the thiol groups of thiolated or cyclic RGD peptides to form stable thioether bonds and DSPE-PEG2000-RGD. DSPE-PEG2000-Maleimide sodium (purity>99%) is applicable to research on drug delivery .
    DSPE-PEG2000-Maleimide sodium (purity>99%)
  • HY-P2300
    Cyclo(Arg-Gly-Asp-D-Phe-Cys)
    2 Publications Verification

    Cyclo(RGDfC)

    		 Integrin Cancer
    Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC), a cyclic RGD peptide which has high affinity to αvβ3, can disrupt cell integrin interactions. Cyclo(Arg-Gly-Asp-D-Phe-Cys) inhibits pluripotent marker expression in embryonic stem cells (ESCs) and the tumorigenic potential of mESCs in vivo. Cyclo(Arg-Gly-Asp-D-Phe-Cys) can be used in the research of tumors .
    Cyclo(Arg-Gly-Asp-D-Phe-Cys)
  • HY-W053583
    Tetraxetan
    1 Publications Verification

    DOTA

    		 Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs) Cancer
    Tetraxetan (DOTA) is a macrocyclic chelating agent. Tetraxetan can form stable coordination complexes with a variety of metal ions (e.g., 68Ga, 111In, 177Lu). Tetraxetan can be conjugated with targeting molecules (e.g., RGD peptide, folic acid) to enable the complex to target specific biomolecules or cells. Tetraxetan can be used for imaging studies of tumors, including melanoma and folate receptor-positive tumors (e.g., cervical cancer) .
    Tetraxetan
  • HY-134130
    Integrin modulator 1
    2 Publications Verification

    		 Integrin Inflammation/Immunology
    Integrin modulator 1 is a potent and selective α4β1 integrin agonist, with an IC50 of 9.8 nM for RGD-binding α4β1. Integrin modulator 1 increases cell adhesion mediated by α4β1 integrin, with an EC50 of 12.9 nM .
    Integrin modulator 1
  • HY-P0290
    GRGDSP
    5 Publications Verification

    		 Integrin Cancer
    GRGDSP, a synthetic linear RGD peptide, is an integrin inhibitor.
    GRGDSP
  • HY-P1408
    Obtustatin
    4 Publications Verification

    		 Integrin VEGFR Cancer
    Obtustatin is a non-RGD disintegrin consisting of 41 residues. Obtustatin inhibits the adhesion of α1β1 integrin to type IV Collagen (HY-NP003), blocks α1β1 integrin signaling in endothelial cells, and suppresses FGF2-induced angiogenesis. Obtustatin inhibits tumor progression in mouse models and upregulates VEGF expression in sarcoma-bearing mice. Obtustatin can be used in research related to Lewis lung carcinoma and S-180 sarcoma .
    Obtustatin
  • HY-19307
    SB-273005

    		Integrin Interleukin Related Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
    SB-273005 is an orally active non-peptide αvβ3 integrin antagonist with Ki values of 1.2 nM and 0.3 nM for αvβ3 and αvβ5, respectively. SB-273005 blocks the binding of integrins to the RGD sequence in the extracellular matrix. SB-273005 inhibits Rictor phosphorylation and reduces IL-10 secretion. SB-273005 inhibits inflammation, prevents bone loss, regulates vascular smooth muscle function, and reverses pregnancy-induced immune deviation. SB-273005 can be used in the study of rheumatoid arthritis, osteoporosis, and aneurysms. .
    SB-273005
  • HY-P0322
    GRGDSPK

    EMD 56574

    		 Integrin Cardiovascular Disease Metabolic Disease
    GRGDSPK (EMD 56574) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK (EMD 56574) is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK is used to study the role of integrins in bone formation and resorption .
    GRGDSPK
  • HY-168940B
    NH2-PEG2000-COOH

    		Drug Intermediate Cancer
    NH2-PEG2000-COOH is a heterofunctional polyethylene glycol with one amino terminal group and one carboxyl terminal group. NH2-PEG2000-COOH reacts with N-succinimidyl-6-maleimidohexanoate to introduce a maleimide terminal group, followed by conjugation with thiolated RGD peptide via a thiol-maleimide coupling reaction to synthesize RGD-PEG-COOH. NH2-PEG2000-COOH can be used in cancer research .
    NH2-PEG2000-COOH
  • HY-P3732
    RGD-4C

    		Integrin Cancer
    RGD-4C is a arginine-glycine-aspartic acid peptide (ACDCRGDCFC) with integrin binding activity. The Arg-Gly-Asp (RGD) sequence serves as the primary integrin recognition site in extracellular matrix proteins, and peptides containing this sequence can mimic the recognition specificity of the matrix proteins. RGD-4C is a αv-integrin ligand, can conjugate with bioactive molecule to exert antitumor effects in animal models .
    RGD-4C
  • HY-P3448
    Certepetide

    CEND-1; iRGD; LSTA1

    		 Integrin Complement System Cancer
    Certepetide (CEND-1) is a bifunctional cyclic peptide (a.k.a. iRGD). Certepetide is a tumor-penetrating enhancer via RGD motif interaction with alphav-integrins and via activating NRP-1, and transforms the solid tumor microenvironment into a temporary agent conduit. Certepetide accumulates in tumors, and is used in the research of pancreatic cancer and other solid tumors .
    Certepetide
  • HY-P99291
    Etaracizumab

    LM609; MEDI-522

    		 Integrin Apoptosis Akt Cancer
    Etaracizumab (LM 609) is an αvβ3 integrin IgG mAb. Etaracizumab is developed to target αvβ3+ cancer cells via NK cell-mediated cytotoxicity. Etaracizumab sterically hinders access of large ligands to the RGD-binding pocket, without obstructing it. Etaracizumab decreases p-Akt in vitro. Etaracizumab can decrease cancer proliferation and invasion. Etaracizumab induces tumor cell apoptosis, and inhibition ofαvβ3-mediated cell adhesion, endothelial cell migration and osteoclast-mediated bone resorption. Etaracizumab can be studied in anti-tumor research against cancers such as ovarian cancer, metastatic melanoma as well as advanced solid tumors. Recommend Isotype Control: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Etaracizumab
  • HY-P0278A
    RGD Trifluoroacetate
    5+ Cited Publications

    		 Integrin Cancer
    RGD Trifluoroacetate is a tripeptide that effectively triggers cell adhesion, addresses certain cell lines and elicits specific cell responses; RGD Trifluoroacetate binds to integrins.
    RGD Trifluoroacetate
  • HY-P1740A
    RGD peptide (GRGDNP) TFA
    5+ Cited Publications

    		 Integrin Apoptosis Inflammation/Immunology Cancer
    RGD peptide (GRGDNP) TFA is an inhibitor of integrin-ligand interactions. RGD peptide (GRGDNP) TFA competitively inhibits α5β1 binding with extracellular matrice (ECM). RGD peptide (GRGDNP) TFA promotes apoptosis through activation of conformation changes that enhance pro-caspase-3 activation and autoprocessing. RGD peptide (GRGDNP) TFA plays an important role in cell adhesion, migration, growth, and differentiation .
    RGD peptide (GRGDNP) TFA
  • HY-P1654
    A20FMDV2

    		Integrin Cancer
    A20FMDV2 is a highly selective αvβ6 integrin inhibitor with human IC50 values of 3 nM and binds with at least 1000-fold selectivity over other RGD-binding integrins. A20FMDV2 binds to the integrin’s RGD-binding site, induces rapid integrin internalization, and delays post-internalization integrin recycling to the cell surface. A20FMDV2 can be used for the research of pancreatic cancer, breast cancer, colorectal cancer, ovarian cancer, oral squamous cell carcinoma .
    A20FMDV2
  • HY-P1189
    Echistatin

    		Integrin Metabolic Disease Inflammation/Immunology
    Echistatin, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of platelet aggregation. Echistatin is a potent inhibitor of bone resorption in culture. Echistatin is a potent antagonist of αIIbβ3, αvβ3 and α5β1 .
    Echistatin
  • HY-10220
    SF1126

    		PI3K Apoptosis Cancer
    SF1126 is a relevant pan and dual first-in-class PI3K/BRD4 inhibitor, has antitumor and anti-angiogenic activity. SF1126 is an RGDS-conjugated LY294002 proagent, which is designed to exhibit increased solubility and bind to specific integrins within the tumor compartment. SF1126 induces cell apoptosis .
    SF1126
  • HY-P5021
    Cyclo(Arg-Gly-Asp-(D-Phe)-Glu)

    c(RGDfE)

    		 Integrin Cancer
    Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) c(RGDfE) is a cyclic RGD peptide targeting integrin αvβ3. Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) is commonly used for modifying drug loaded nanoparticles. Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) is often used in cancer research, such as pancreatic cancer .
    Cyclo(Arg-Gly-Asp-(D-Phe)-Glu)
  • HY-166648A
    DSPE-PEG-Maleimide ammonium (MW 2000)
    1 Publications Verification

    		 Liposome Others
    DSPE-PEG-Maleimide ammonium (MW 2000) is a functional lipid component and a thiol-reactive crosslinker. DSPE-PEG-Maleimide ammonium (MW 2000) undergoes Michael addition with the thiol groups of thiolated or cyclic RGD peptides to form stable thioether bonds and DSPE-PEG (2000)-RGD. DSPE-PEG-Maleimide ammonium (MW 2000) is applicable to research on drug delivery .
    DSPE-PEG-Maleimide ammonium (MW 2000)
  • HY-P4896
    FITC-Ahx-Gly-Arg-Gly-Asp-Ser-Pro

    		Integrin Cancer
    FITC-Ahx Gly Arg Gly Asp Ser Pro is a GRGDSP (HY-P0290) coupled to FITC. GRGDSP is an integrin inhibitor that can inhibit the adherence of tumor cells to endothelial cells of blood vessels and limit its metastasis .
    FITC-Ahx-Gly-Arg-Gly-Asp-Ser-Pro
  • HY-P1189A
    Echistatin TFA

    		Integrin Metabolic Disease Inflammation/Immunology
    Echistatin TFA, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of platelet aggregation. Echistatin is a potent inhibitor of bone resorption in culture. Echistatin is a potent antagonist of αIIbβ3, αvβ3 and α5β1 .
    Echistatin TFA
  • HY-P0178
    LXW7

    		Integrin Inflammation/Immunology
    LXW7, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC50 of 0.68 μM. LXW7 increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect .
    LXW7
  • HY-P2300A
    Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA
    2 Publications Verification

    Cyclo(RGDfC) TFA

    		 Integrin Cancer
    Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC) TFA, a cyclic RGD peptide which has high affinity to αvβ3, can disrupt cell integrin interactions. Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA inhibits pluripotent marker expression in embryonic stem cells (ESCs) and the tumorigenic potential of mESCs in vivo. Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA can be used in the research of tumors .
    Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA
  • HY-P2219A
    CGGRGD TFA

    		Amino Acid Derivatives Cancer
    CGGRGD TFA, a RGD derivative with cysteine as its N-terminal .
    CGGRGD TFA
  • HY-P4907
    RGD Negative Control

    		Integrin Others
    RGD Negative Control is the negative control of RGD (HY-P0278).
    RGD Negative Control
  • HY-P11339
    c-RGD-SH

    		Integrin Cancer
    c-RGD-SH is a ligand for integrin αvβ3 (Integrin αvβ3). Conjugation of c-RGD-SH with core-crosslinked polymeric micelles (CCPM) enables the synthesis of a bimodal nanoprobe, which can be labeled with Cy7 and 111In for SPECT and NIRF imaging of tumors .
    c-RGD-SH
  • HY-W1048555A
    Mal-PEG2000-SCM

    		Biochemical Assay Reagents Others
    Mal-PEG2000-SCM is a heterobifunctional PEG crosslinker bearing maleimide and succinimidyl carboxymethyl ester functional groups. MMal-PEG2000-SCM conjugates the F3 peptide to nanoparticles: the SCM group reacts with amino groups on the nanoparticle surface to form amide groups, while the MAL group reacts with thiol groups of the F3 peptide to form carbon-sulfur bonds. Mal-PEG-SCM enables unidirectional addition of linkers, ensuring that appropriate functional groups are available for RGD incorporation. Mal-PEG2000-SCM can be used in the development of nanoparticles targeting specific tumor cells .
    Mal-PEG2000-SCM
  • HY-P10941A
    VSLRGDTRG acetate

    		Integrin FAK ERK Inflammation/Immunology Cancer
    VSLRGDTRG acetate is a synthetic peptide containing the RGD motif from cadherin 17 (CDH17), which binds to α2β1 integrin and activates its signaling pathway. VSLRGDTRG acetate promotes the high-affinity conformational change of β1 integrin through the RGD motif, enhancing cell adhesion and phosphorylation of FAK and ERK1/2, thereby driving tumor proliferation and metastasis. VSLRGDTRG acetate can be used in research on cancers expressing CDH17, such as colon cancer and pancreatic cancer .
    VSLRGDTRG acetate
  • HY-P1930A
    Risuteganib hydrochloride

    		Integrin Inflammation/Immunology
    Risuteganib hydrochloride is a synthetic RGD (arginyl-glycyl-aspartic acid)-class peptide. Risuteganib hydrochloride is an anti-integrin that downregulates oxidative stress and restores homeostasis, and targets three integrin receptors that are implicated in dry age-related macular degeneration (AMD) in order to restore homeostasis in the retina .
    Risuteganib hydrochloride
  • HY-P2219
    CGGRGD

    		Amino Acid Derivatives Cancer
    CGGRGD, a RGD derivative with cysteine as its N-terminal .
    CGGRGD
  • HY-D2439
    RGD-PEG-Cy3

    		Fluorescent Dye Cancer
    RGD-PEG-Cy3 is a fluorescent labeling reagent that combines Cy3 fluorescent dye, peptide (RGD) and polyethylene glycol (PEG). The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. Cy3 has an emission maximum around 562-570 nm. RGD is a peptide sequence (CRGDKGPDCiRGD) that binds to αvβ3 and αvβ5 integrin receptors on tumor neovasculogenesis to achieve specific tumor tissue targeting .
    RGD-PEG-Cy3
  • HY-P0309A
    Arg-Gly-Glu-Ser TFA

    		Integrin Inflammation/Immunology
    Arg-Gly-Glu-Ser TFA is a polypeptide related to RGD and is a negative control for Arg-Gly-Asp-Ser (HY-12290) .
    Arg-Gly-Glu-Ser TFA
  • HY-161730
    αvβ1 integrin-IN-3

    		Integrin Cardiovascular Disease Cancer
    αvβ1 integrin-IN-3 is a selective αvβ1 integrin inhibitor. αvβ1 integrin-IN-3 has an antifibrotic effect .
    αvβ1 integrin-IN-3
  • HY-P10941
    VSLRGDTRG

    		Integrin FAK ERK Inflammation/Immunology Cancer
    VSLRGDTRG is a synthetic peptide containing the RGD motif from cadherin 17 (CDH17), which binds to α2β1 integrin and activates its signaling pathway. VSLRGDTRG promotes the high-affinity conformational change of β1 integrin through the RGD motif, enhancing cell adhesion and phosphorylation of FAK and ERK1/2, thereby driving tumor proliferation and metastasis. VSLRGDTRG can be used in research on cancers expressing CDH17, such as colon cancer and pancreatic cancer .
    VSLRGDTRG
  • HY-P1408A
    Obtustatin triacetate
    4 Publications Verification

    		 Integrin Cancer
    Obtustatin triacetate is a 41-residue non-RGD disintegrin. Obtustatin triacetate can be isolated from the venom of Vipera lebetina obtusa. Obtustatin triacetate is a potent and selective inhibitor of integrin α1β1 adhesion to type IV collagen. Obtustatin triacetate inhibits angiogenesis and may be used in cancer research .
    Obtustatin triacetate
  • HY-P3525A
    G-Pen-GRGDSPCA TFA

    		Integrin Others
    G-Pen-GRGDSPCA TFA is an αvβ3-inhibiting RGD peptide. G-Pen-GRGDSPCA can limit neointimal hyperplasia and lumen stenosis after vascular injury, as well as regulate the migration and proliferation of smooth muscle cells. G-Pen-GRGDSPCA TFA can be used in the study of the mechanism of vascular injury repair .
    G-Pen-GRGDSPCA TFA
  • HY-P0178A
    LXW7 TFA

    		Integrin Inflammation/Immunology
    LXW7 TFA, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC50 of 0.68 μM. LXW7 TFA increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect .
    LXW7 TFA
  • HY-W053583R
    Tetraxetan (Standard)

    DOTA (Standard)

    		 Biochemical Assay Reagents Reference Standards Radionuclide-Drug Conjugates (RDCs) Cancer
    Tetraxetan (Standard) is the analytical standard of Tetraxetan (HY-W053583). This product is intended for research and analytical applications. Tetraxetan (DOTA) is a macrocyclic chelating agent. Tetraxetan can form stable coordination complexes with a variety of metal ions (e.g., 68Ga, 111In, 177Lu). Tetraxetan can be conjugated with targeting molecules (e.g., RGD peptide, folic acid) to enable the complex to target specific biomolecules or cells. Tetraxetan can be used for imaging studies of tumors, including melanoma and folate receptor-positive tumors (e.g., cervical cancer) .
    Tetraxetan (Standard)
  • HY-RS11633
    RALGDS Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    RALGDS Human Pre-designed siRNA Set A contains three designed siRNAs for RALGDS gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    RALGDS Human Pre-designed siRNA Set A
    RALGDS Human Pre-designed siRNA Set A
  • HY-P11339A
    c-RGD-SH TFA

    		Integrin Cancer
    c-RGD-SH TFA is an Integrin αvβ3 ligand. c-RGD-SH TFA conjugated with core-crosslinked polymeric micelles (CCPM) can be used for synthesis a dual modality nanoparticle probe, and this probe labeled with both Cy7 and 111In can be used for SPECT and NIRF imaging of tumor .
    c-RGD-SH TFA
  • HY-175323
    NOTA-IMB-RGD

    		Integrin PD-1/PD-L1 Cancer
    NOTA-IMB-RGD is a dual molecular probe targeting integrin αvβ3 and programmed death ligand-1 (PD-L1). NOTA-IMB-RGD blocks the PD-1/PD-L1 signaling pathway and integrin αvβ3-overexpressing tumor vasculature. NOTA-IMB-RGD is promising for research of solid tumors co-expressing PD-L1 and αvβ3 (e.g., glioma, breast cancer) .
    NOTA-IMB-RGD
  • HY-P2153
    Maraciclatide

    		Integrin Inflammation/Immunology Cancer
    Maraciclatide is a synthetic molecule that binds with high affinity to αvβ3 and αvβ5 integrins via the RGD peptide. Maraciclatide can be used to detect bone metastasis, breast tumors, vascular disease and rheumatoid arthritis in animal models. Maraciclatide can be studied in research on angiogenesis and inflammation .
    Maraciclatide
  • HY-P3525
    G-Pen-GRGDSPCA

    		Integrin Others
    G-Pen-GRGDSPCA is an αvβ3-inhibiting RGD peptide. G-Pen-GRGDSPCA can limit neointimal hyperplasia and lumen stenosis after vascular injury, as well as regulate the migration and proliferation of smooth muscle cells. G-Pen-GRGDSPCA can be used in the study of the mechanism of vascular injury repair .
    G-Pen-GRGDSPCA
  • HY-P11215
    GCGGRGDSPG

    		Biochemical Assay Reagents Others
    GCGGRGDSPG is a thiolated cell-adhesive RGD peptide .
    GCGGRGDSPG
  • HY-P5053
    Galacto-RGD

    		Radionuclide-Drug Conjugates (RDCs) Integrin Cancer
    Galacto-RGD is an RGD analogue that can be coupled with the radioactive isotope 18F and used as an integrin α β selective tracer . Galacto-RGD can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    Galacto-RGD
  • HY-N15786
    DSPE-RGD Lipid sodium

    		Biochemical Assay Reagents Cancer
    DSPE-RGD Lipid sodium is a lipid containing DSPE and RGD peptides that can be used to prepare lipid nanoparticles for drug delivery.
    DSPE-RGD Lipid sodium
  • HY-N15803
    DOPE-RGD Lipid sodium

    		Biochemical Assay Reagents Cancer
    DOPE-RGD Lipid sodium is a lipid containing DOPE and RGD peptides that can be used to prepare lipid nanoparticles for drug delivery.
    DOPE-RGD Lipid sodium

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: